Aoxin Q&M posts FY2025 net profit after tax of CNY6.9 million as FY2024 net loss of CNY8.0 million reverses to profit

Reuters
02/28
Aoxin Q&M posts FY2025 net profit after tax of CNY6.9 million as FY2024 net loss of CNY8.0 million reverses to profit

Aoxin Q&M Dental reported FY2025 net profit after tax of RMB6.9 million, compared with a net loss in FY2024, as it cited a substantial reduction in losses from its share of results of an associate. FY2025 revenue was RMB171.0 million (down 3.6%), while FY2025 EBITDA was RMB24.1 million. Net profit after tax excluding share of results of associate was RMB7.0 million (up 11.6%). In 2H2025, revenue was RMB84.2 million (down 10.8%) and net profit after tax was RMB4.2 million. The share of results of associate in FY2025 was a loss of RMB0.03 million. As at 31 December 2025, net assets were RMB349.3 million and cash and cash equivalents were RMB148.7 million following completion of a rights issue that raised net proceeds of RMB82.8 million. The group said it plans to allocate RMB43.7 million of the proceeds for business expansion, including mergers and acquisitions, joint ventures and partnerships, and RMB27.3 million for investment in property, plant and equipment, while also highlighting expansion of its lab services business into Singapore and other regional countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aoxin Q&M Dental Group Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: R326Z1ZBSHNEBOJL) on February 28, 2026, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10